Evome Medical Technologies Inc.
LNDZF
$0.0112
-$0.0488-81.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -50.78% | -39.16% | 9.95% | 36.21% | 70.83% |
| Total Revenue | -50.78% | -39.16% | 9.95% | 36.21% | 70.83% |
| Cost of Revenue | -51.23% | -40.13% | 30.16% | 26.07% | 69.51% |
| Gross Profit | 69.33% | 48.87% | -3,687.76% | 30.19% | -29.39% |
| SG&A Expenses | -- | -- | -- | -- | -- |
| Depreciation & Amortization | -32.94% | -30.63% | 11.10% | 49.78% | 105.30% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.18% | -39.56% | 28.62% | 27.55% | 71.22% |
| Operating Income | 43.31% | 41.71% | -228.06% | 5.88% | -75.90% |
| Income Before Tax | -137.70% | -100.33% | -164.37% | -83.84% | 129.55% |
| Income Tax Expenses | -100.00% | 405.88% | -- | 100.25% | 113.42% |
| Earnings from Continuing Operations | -137.82% | -100.95% | -158.61% | -213.61% | 129.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -137.82% | -100.95% | -158.61% | -213.61% | 129.66% |
| EBIT | -- | -- | -- | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -132.17% | -50.00% | -87.31% | -138.83% | 120.83% |
| Normalized Basic EPS | -75.76% | 41.33% | -69.81% | 50.00% | 78.98% |
| EPS Diluted | -132.17% | -50.00% | -87.31% | -138.83% | 120.72% |
| Normalized Diluted EPS | -75.76% | 41.33% | -69.81% | 50.00% | 78.98% |
| Average Basic Shares Outstanding | 16.91% | 33.71% | 37.94% | 31.37% | 42.50% |
| Average Diluted Shares Outstanding | 16.91% | 33.71% | 37.94% | 31.37% | 42.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
